Immune-mediated hemolytic anemia is one of the possible complications after both solid organ and allogeneic SCT (ASCT), potentially associated with significant morbidity, including severe hemolysis and acute renal failure.
1 Death from massive hemolysis has also been reported in the literature. 2 Passenger lymphocyte syndrome (PLS) is occasionally a cause of hemolysis in these patients. PLS occurs between day 5 and 15 post transplant when a minor ABO incompatibility exists between the donor and the recipient (most common A þ recipient, O þ donor). Immunocompetent donor B-lymphocytes transferred passively with the graft maintain their ability to generate antibodies, which bind to the recipient's RBCs causing hemolysis. [3] [4] [5] [6] The treatment of PLS has been mainly supportive, with or without immunosuppression. 1, 6 This report describes the first experience with the use of rituximab (Rituxan, Genentech, South San Francisco, CA, USA) for the treatment of PLS in an ASCT patient and reviews the accumulated data regarding the transfusion requirement for patients with PLS after ASCT.
A 65-year-old woman with chronic myelomonocytic leukemia was admitted for an ASCT from a 10/10 HLAmatched unrelated donor. A minor ABO mismatch was present between the donor and the recipient (group A, Rh þ ) and the donor (group O, Rh þ ). The preparative regimen consisted of gemtuzumab ozogamicin 2 mg/m 2 on day -12, fludarabine 25 mg/m 2 i.v. days À7 to À4, melphalan 70 mg/m 2 on days À4 and À3. GVHD prophylaxis was employed with rabbit anti-thymocyte globulin 0.5 mg/kg on day À3 and 1.25 mg/kg on days À2 and À1, tacrolimus and 'miniMTX' 5 mg/m 2 on days 1, 3, 6 and 11 post transplant. 7 The patient received a BM graft containing 3.1 Â 10 6 CD34 þ cells per kg and 21.8 Â 10 4 CD3 þ cells per kg. No graft manipulation was performed. The post transplant course was uneventful until day 6, when the patient developed mild indirect bilirubinemia and increased lactate dehydrogenase. This evolved over the next 2 days to full hemolytic anemia, with rapid drop in Hb to 6 g per 100ml, increase lactate dehydrogenase to 1051 IU/l, further rise in indirect bilirubinemia to 3.0 mg per 100ml (total bilirubinemia 3.6 mg per 100ml), low haptoglobin (22 mg per 100ml) and hemoglobinuria. The peripheral blood smear revealed numerous spherocytes. On day 7, a direct Coomb's test (DAT) was strongly positive (3 þ ) for IgG and complement. Anti-A IgG antibodies were elutriated off the surface of the RBCs. Patient's plasma showed no evidence of anti RBC antibodies. The patient began transfusion with packed RBCs (PRBCs) and started steroids, methylprednisolone 2.5 mg/kg/day. Owing to extensive hemolysis, one dose of rituximab 375 mg/kg was given on day 8 after transplant. This was associated with a rapid resolution of the hemolytic process, which lasted for only 3 days (Figure 1) . Out of seven units of PRBCs, the patient received two units on day 7, four units on day 8 and one unit on day 9. A repeat DAT was not performed until day 20 post transplant, when it was found to be negative.
PLS is an intriguing immunological phenomenon described both in solid organ and ASCT.
1 Several risk factors for the development of PLS have been postulated in the literature including the degree of mismatch, peripheral stem cell source, amount of lymphoid tissue transplanted and the use of CYA/tacrolimus without MTX for GVHD prophylaxis. 1, 6, 8 Treatment has been transfusion with donor ABO compatible PRBCs (O þ PRBCs are used in this setting) and steroids, occasionally plasma or red cell exchange and adequate kidney perfusion.
1, 6 Rituximab, a chimeric monoclonal antibody directed against CD 20 þ Blymphocytes, has been tried in hemolytic anemia of other causes and its use in PLS would make intuitive sense. Rituximab has been successfully used in one pediatric solid organ transplantation case and in two pediatric cases of late onset hemolytic anemia. 5, 9, 10 Our patient displayed typical features of PLS for which rituximab, in addition to O þ PRBCs and steroids, aborted the massive intravascular hemolysis soon after its onset. MTX has also been shown to mitigate hemolysis secondary to PLS; however, pretreated patients with MTX and anti-thymocyte globulin still appear to be susceptible to the development of this clinical entity. 3, 8 A lower dose of MTX as in the miniMTX regimen received by this patient could be less efficacious in preventing PLS. Such patients may benefit from the use of rituximab in case severe hemolysis develops.
We reviewed 27 cases of PLS associated with ASCT reported in the English literature (search on 11/21/07 PubMed/Ovid/Medline for passenger lymphocyte syndrome/minor ABO mismatch/ASCT) for which the duration of hemolysis and the number of PRBCs units transfused were reported (Table 1 ). The median number of days of hemolysis was 8 (range: 4-30), while the median number of PRBCs transfused was 9 (range: 5-31). Only in the PLS case treated with rituximab, the duration of hemolysis lasted for 5 days and the number of PRBCs units transfused was seven. 5 Although the experience is very limited, these findings suggest that rituximab may be an effective therapy to minimize severe hemolysis associated with PLS. Further evaluation could better determine its efficacy and provide more insight into the mechanisms of action in this disease. Abbreviation: CGL, chronic granulocytic leukemia; CTCL, cutaneous T-cell lymphoma; DX, diagnosis; mm, multiple myeloma; NHL, non-Hodgkins lymphoma; PLS, passenger lymphocyte syndrome; SAA, severe aplastic anemia; TPLL, T-cell prolymphocytic leukemia.
